Independent Financial Group LLC Buys Shares of 4,319 Thermo Fisher Scientific Inc. $TMO

Independent Financial Group LLC purchased a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 4,319 shares of the medical research company’s stock, valued at approximately $2,123,000.

A number of other institutional investors have also recently made changes to their positions in TMO. High Note Wealth LLC increased its position in Thermo Fisher Scientific by 170.6% during the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after buying an additional 29 shares in the last quarter. Swiss RE Ltd. purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $28,000. JPL Wealth Management LLC acquired a new position in shares of Thermo Fisher Scientific during the third quarter valued at about $28,000. Beacon Financial Strategies CORP purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $29,000. Finally, Olistico Wealth LLC acquired a new stake in Thermo Fisher Scientific in the 4th quarter worth approximately $29,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $532.17 on Friday. The company has a 50 day simple moving average of $484.57 and a two-hundred day simple moving average of $514.88. The stock has a market cap of $197.77 billion, a price-to-earnings ratio of 29.26, a PEG ratio of 2.36 and a beta of 0.87. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77. Thermo Fisher Scientific Inc. has a 12 month low of $403.36 and a 12 month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.25 by $0.19. The firm had revenue of $11.01 billion during the quarter, compared to analysts’ expectations of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The firm’s revenue was up 6.2% compared to the same quarter last year. During the same quarter last year, the company posted $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 24.84 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.34%.

Insider Activity

In other news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the sale, the chief operating officer owned 25,051 shares in the company, valued at $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on TMO. Evercore set a $570.00 price target on shares of Thermo Fisher Scientific in a research note on Monday, July 6th. Wells Fargo & Company lowered their price objective on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Sanford C. Bernstein initiated coverage on Thermo Fisher Scientific in a research report on Friday, June 26th. They issued a “market perform” rating and a $520.00 target price on the stock. Wolfe Research started coverage on Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 target price for the company. Finally, Wall Street Zen downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $602.14.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.